Previous 10 | Next 10 |
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen PR Newswire NEWARK, Calif., Oct. 29, 2020 NEWARK, Calif. , Oct. 29, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today...
NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300. Genmab reports positive data from Phase 2 CASSIOPEIA study. For further details see: NantKwest COVID-19 Candidate, And Other ...
The European Medicines Agency has designated Orphan Drug status to Protagonist Therapeutics's (PTGX) PTG-300 for the treatment of polycythemia vera, a type of blood cancer in which the bone marrow produces too many red blood cells.PTG-300 is an injectable synthetic peptide mimetic o...
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera -- PTG-300 was previously granted orphan drug designation by the U.S. Food and Drug Administration -- PR Newswire NEWARK, Calif., Oct. 21, 2020 ...
NEWARK, Calif. , Sept. 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Virtual Su...
NEWARK, Calif. , Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment...
NEWARK, Calif. , Sept. 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced it will host a "PTG-300 Opportunity Update" webinar on Friday, Sept. 11, 2020 , from 12 p.m. to 1:30 p.m. EDT . The event will feature presentations on clinical needs in pol...
The biotech industry has been on a tear as the search for coronavirus treatments heat up. Here are four biotech stocks that analysts love: Compugen (CGEN), Cerus (CERS), Mersana Therapeutics (MRSN) and Protagonist Therapeutics (PTGX). Wall Street analysts keep a close eye on price movement,...
Protagonist (NASDAQ: PTGX ) : Q2 GAAP EPS of -$0.59 misses by $0.02 . More news on: Protagonist Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEWARK, Calif. , Aug. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported financial results for the second quarter ended June 30, 2020 , and provided an update on clinical development programs. "We have succeeded in bringing three differentiated ca...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...